Search Press releases Keywords From To 30 Jun 2023 UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at 9th Congress of the European Academy of Neurology (EAN) Meeting Read More 27 Jun 2023 UCB announces U.S. FDA approval of RYSTIGGO[®] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis Read More 26 Jun 2023 UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab Read More 26 Jun 2023 Change in UCB’s Executive Committee Read More 20 Jun 2023 UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress Read More 7 Jun 2023 UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis Read More Pagination First page Previous page Previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
